Insmed Extends ALIS Intellectual Property Protection to 2035 with Issuance of Ninth U.S. Patent
February 20 2018 - 8:00AM
Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical
company focused on the unmet needs of patients with rare diseases,
today announced that the United States Patent and Trademark Office
(USPTO) issued U.S. Patent Number 9,895,385 concerning methods for
treating nontuberculous mycobacterial (NTM) lung infections,
including NTM lung infections caused by Mycobacterium avium complex
(MAC), with the Company’s amikacin liposome inhalation suspension
(ALIS). The claims of the patent relate to methods for treating MAC
lung infections via administration of ALIS to non-cystic fibrosis
patients by nebulization once daily for a defined treatment period.
The patent extends previously existing patent coverage for ALIS by
sixteen months, from January 2034 into May 2035. Insmed is
currently on track to file its New Drug Application (NDA) for
accelerated approval of ALIS with the U.S. Food and Drug
Administration (FDA) before the end of March.
“The term of this new patent could run almost
five years beyond our regulatory designations in the United States,
and is therefore a key addition to our growing patent estate for
ALIS, which now includes nine issued US patents,” said Will Lewis,
President and Chief Executive Officer of Insmed. “Insmed places an
emphasis on strategies for protecting ALIS and its other key assets
in line with potential market opportunities and will continue to
pursue additional patents in major markets worldwide to further
enhance the value potential of ALIS.”
About Insmed
Insmed Incorporated is a global
biopharmaceutical company focused on the unmet needs of patients
with rare diseases. The Company’s lead product candidate is ALIS
for adult patients with treatment refractory NTM lung disease
caused by MAC, which is a rare and often chronic infection that is
capable of causing irreversible lung damage and can be fatal.
Insmed's earlier-stage clinical pipeline includes INS1007, a novel
oral reversible inhibitor of dipeptidyl peptidase 1 with
therapeutic potential in non-cystic fibrosis bronchiectasis and
other inflammatory diseases and INS1009, an inhaled nanoparticle
formulation of a treprostinil prodrug that may offer a
differentiated product profile for rare pulmonary disorders,
including pulmonary arterial hypertension. For more
information, visit www.insmed.com.
Forward-looking Statements
This press release contains forward-looking
statements that involve substantial risks and uncertainties.
"Forward-looking statements," as that term is defined in the
Private Securities Litigation Reform Act of 1995, are statements
that are not historical facts and involve a number of risks and
uncertainties. Words such as "may," "will," "should," "could,"
"would," "expects," "plans," "anticipates," "believes,"
"estimates," "projects," "predicts," "intends," "potential,"
"continues," and similar expressions (as well as other words or
expressions referencing future events, conditions or circumstances)
identify forward-looking statements.
The forward-looking statements in this press
release are based upon the Company’s current expectations and
beliefs, and involve known and unknown risks, uncertainties and
other factors, which may cause the Company’s actual results,
performance and achievements and the timing of certain events to
differ materially from the results, performance, achievements or
timing discussed, projected, anticipated or indicated in any
forward-looking statements. Such risks, uncertainties and other
factors include, among others, the following: risks that the full
six-month data from the CONVERT study or subsequent data from the
remainder of the study’s treatment and off-treatment phases will
not be consistent with the top-line six-month results of the study;
uncertainties in the research and development of the Company’s
existing product candidates, including due to delays in data
readouts, such as the full data from the CONVERT study, patient
enrollment and retention or failure of the Company’s preclinical
studies or clinical trials to satisfy pre-established endpoints,
including secondary endpoints in the CONVERT study and endpoints in
the CONVERT extension study (the 312 study); risks that subsequent
data from the 312 study will not be consistent with the interim
results; failure to obtain, or delays in obtaining, regulatory
approval from the U.S. Food and Drug Administration, Japan’s
Ministry of Health, Labour and Welfare, Japan’s Pharmaceuticals and
Medical Devices Agency, the European Medicines Agency, and other
regulatory authorities for the Company’s product candidates or
their delivery devices, such as the eFlow Nebulizer System,
including due to insufficient clinical data, selection of endpoints
that are not satisfactory to regulators, complexity in the review
process for combination products or inadequate or delayed data from
a human factors study required for U.S. regulatory approval;
failure to maintain regulatory approval for the Company’s product
candidates, if received, due to a failure to satisfy post-approval
regulatory requirements, such as the submission of sufficient data
from confirmatory clinical studies; safety and efficacy concerns
related to the Company’s product candidates; lack of experience in
conducting and managing preclinical development activities and
clinical trials necessary for regulatory approval, including the
regulatory filing and review process; failure to comply with
extensive post-approval regulatory requirements or imposition of
significant post-approval restrictions on the Company’s product
candidates by regulators; uncertainties in the rate and degree of
market acceptance of product candidates, if approved; inability to
create an effective direct sales and marketing infrastructure or to
partner with third parties that offer such an infrastructure for
distribution of the Company’s product candidates, if approved;
inaccuracies in the Company’s estimates of the size of the
potential markets for the Company’s product candidates or
limitations by regulators on the proposed treatment population for
the Company’s product candidates; failure of third parties on which
the Company is dependent to conduct the Company’s clinical trials,
to manufacture sufficient quantities of the Company’s product
candidates for clinical or commercial needs, including the
Company’s raw materials suppliers, or to comply with the Company’s
agreements or laws and regulations that impact the Company’s
business; inaccurate estimates regarding the Company’s future
capital requirements, including those necessary to fund the
Company’s ongoing clinical development, regulatory and
commercialization efforts as well as milestone payments or
royalties owed to third parties; failure to develop, or to license
for development, additional product candidates, including a failure
to attract experienced third-party collaborators; uncertainties in
the timing, scope and rate of reimbursement for the Company’s
product candidates; changes in laws and regulations applicable to
the Company’s business and failure to comply with such laws and
regulations; inability to repay the Company’s existing indebtedness
or to obtain additional capital when needed on desirable terms or
at all; failure to obtain, protect and enforce the Company’s
patents and other intellectual property and costs associated with
litigation or other proceedings related to such matters;
restrictions imposed on the Company by license agreements that are
critical for the Company’s product development, including the
Company’s license agreements with PARI Pharma GmbH and AstraZeneca
AB, and failure to comply with the Company’s obligations under such
agreements; competitive developments affecting the Company’s
product candidates and potential exclusivity related thereto; the
cost and potential reputational damage resulting from litigation to
which the Company is a party, including, without limitation, the
class action lawsuit pending against the Company; loss of key
personnel; lack of experience operating internationally; and risks
that the net proceeds from our offerings of our securities are not
spent as currently intended or in ways that enhance the value of
your investment.
We may not actually achieve the results, plans,
intentions or expectations indicated by our forward-looking
statements because, by their nature, forward-looking statements
involve risks and uncertainties because they relate to events and
depend on circumstances that may or may not occur in the future.
For additional information about the risks and uncertainties that
may affect the Company’s business, please see the factors discussed
in Item 1A, "Risk Factors," in the Company’s Quarterly Report on
Form 10-Q for the three months ended September 30, 2017 and any
subsequent filings with the Securities and Exchange Commission.
The Company cautions readers not to place undue
reliance on any such forward-looking statements, which speak only
as of the date of this press release. The Company disclaims any
obligation, except as specifically required by law and the rules of
the Securities and Exchange Commission, to publicly update or
revise any such statements to reflect any change in expectations or
in events, conditions or circumstances on which any such statements
may be based, or that may affect the likelihood that actual results
will differ from those set forth in the forward-looking statements.
You should read this press release with the understanding that our
actual future results may be materially different from those
expressed in forward-looking statements.
Contact:
Blaine Davis Insmed Incorporated (908) 947-2841
blaine.davis@insmed.com
Insmed (NASDAQ:INSM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Insmed (NASDAQ:INSM)
Historical Stock Chart
From Apr 2023 to Apr 2024